الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 147 |  |  |
| | | from | 147 | | |
Abstract
This study aimed to : Livin, a member of the inhibitor of apoptosis proteins (IAP) has been considered to be a poor prognostic marker in malignancies. However, a little is known about the clinical relevance of Livin expression in childhood acute leukemia. This work was to assess the expression of Livin on leukemic blasts of de novo childhood acute leukemia and its relevance to clinical and hematological findings, and treatment outcome.
Patients and methods: The expression of Livin was analyzed in 100 patients with newly diagnosed acute childhood leukemia (80acute lymphoblastic leukemia and 20 acute myeloblastic leukemia) using quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR).
Results:The results of the study revealed that the expression levels of Livin were higher in ALL patients with favorable prognostic factors. Furthermore, Livin expression was associated with a favorable early response to chemotherapy (leukemic blast <25% day 7 bone marrow response) [P<0.001]. Patients with +ve Livin expression were associated with significantly higher CR rate (P = 0.001) than those with -veLivin expression. While in AML patients Livin was neither significantly higher in patients with favorable prognostic factors nor better treatment outcome [P=0.054]
Conclusions:This study suggests that Livin expression could be a novel favorable prognostic marker in childhood acute lymphoblastic leukemia and thus, it could be incorporated into the patient stratification and treatment protocols, however not for acute myeloblastic leukemia.
Key words: Acute lymphoblastic leukemia, Acute myeloblastic leukemia, Livin, RT-PCR.
Background/ aim of the study: Livin, a member of the inhibitor of apoptosis proteins (IAP) has been considered to be a poor prognostic marker in malignancies. However, a little is known about the clinical relevance of Livin expression in childhood acute leukemia. This work was to assess the expression of Livin on leukemic blasts of de novo childhood acute leukemia and its relevance to clinical and hematological findings, and treatment outcome.
Patients and methods: The expression of Livin was analyzed in 100 patients with newly diagnosed acute childhood leukemia (80acute lymphoblastic leukemia and 20 acute myeloblastic leukemia) using quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR).
Results:The results of the study revealed that the expression levels of Livin were higher in ALL patients with favorable prognostic factors. Furthermore, Livin expression was associated with a favorable early response to chemotherapy (leukemic blast <25% day 7 bone marrow response) [P<0.001]. Patients with +ve Livin expression were associated with significantly higher CR rate (P = 0.001) than those with -veLivin expression. While in AML patients Livin was neither significantly higher in patients with favorable prognostic factors nor better treatment outcome [P=0.054]
Conclusions:This study suggests that Livin expression could be a novel favorable prognostic marker in childhood acute lymphoblastic leukemia and thus, it could be incorporated into the patient stratification and treatment protocols, however not for acute myeloblastic leukemia.
Key words: Acute lymphoblastic leukemia, Acute myeloblastic leukemia, Livin, RT-PCR.